On Wednesday, the U.S. Food and Drug Administration’s Dr. Binita Ashar released a statement on the danger of women getting cancer after having breast implants. As CNN reported, “At least 457 women in the United States have so far been diagnosed with anaplastic large cell lymphoma. … Of those, nine have died as a result of the rare cancer, which affects cells in the immune system and can be found around the breast implant.” Anaplastic large cell lymphoma is a type of non-Hodgkin’s lymphoma.
The American Society for Aesthetic Plastic Surgery and the American Society of Plastic Surgeons has written: “BIA-ALCL usually develops as a delayed swelling of the breast (Average 8 years, range 2 to 28 years) after the insertion of textured breast implants, which may present as fluid collecting around the implant or marked breast asymmetry. It can also present as a lump in the breast or armpit.”
The FDA statement said, “We recognize the limitations of medical device reports, which is why we review other sources of information, including medical literature and the Patient Registry and Outcomes for Breast Implants and Anaplastic Large Cell Lymphoma Etiology and Epidemiology. PROFILE collects real world data regarding patients who have a confirmed diagnosis of BIA-ALCL. Our participation in this registry reflects the FDA’s commitment to implementing our Medical Device Safety Action Plan, in which we are streamlining and modernizing how we implement postmarket actions to address device safety issues to make our responses to risks more timely and effective.” (Read more from “Implants Increasingly Linked to Lymphoma in Women – 9 Reported Deaths” HERE)